Cargando…
Peptide therapeutics in the management of metastatic cancers
Cancer remains a leading health concern threatening lives of millions of patients worldwide. Peptide-based drugs provide a valuable alternative to chemotherapeutics as they are highly specific, cheap, less toxic and easier to synthesize compared to other drugs. In this review, we have discussed vari...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345020/ https://www.ncbi.nlm.nih.gov/pubmed/35975072 http://dx.doi.org/10.1039/d2ra02062a |
_version_ | 1784761338434682880 |
---|---|
author | Bose, Debopriya Roy, Laboni Chatterjee, Subhrangsu |
author_facet | Bose, Debopriya Roy, Laboni Chatterjee, Subhrangsu |
author_sort | Bose, Debopriya |
collection | PubMed |
description | Cancer remains a leading health concern threatening lives of millions of patients worldwide. Peptide-based drugs provide a valuable alternative to chemotherapeutics as they are highly specific, cheap, less toxic and easier to synthesize compared to other drugs. In this review, we have discussed various modes in which peptides are being used to curb cancer. Our review highlights specially the various anti-metastatic peptide-based agents developed by targeting a plethora of cellular factors. Herein we have given a special focus on integrins as targets for peptide drugs, as these molecules play key roles in metastatic progression. The review also discusses use of peptides as anti-cancer vaccines and their efficiency as drug-delivery tools. We hope this work will give the reader a clear idea of the mechanisms of peptide-based anti-cancer therapeutics and encourage the development of superior drugs in the future. |
format | Online Article Text |
id | pubmed-9345020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-93450202022-08-15 Peptide therapeutics in the management of metastatic cancers Bose, Debopriya Roy, Laboni Chatterjee, Subhrangsu RSC Adv Chemistry Cancer remains a leading health concern threatening lives of millions of patients worldwide. Peptide-based drugs provide a valuable alternative to chemotherapeutics as they are highly specific, cheap, less toxic and easier to synthesize compared to other drugs. In this review, we have discussed various modes in which peptides are being used to curb cancer. Our review highlights specially the various anti-metastatic peptide-based agents developed by targeting a plethora of cellular factors. Herein we have given a special focus on integrins as targets for peptide drugs, as these molecules play key roles in metastatic progression. The review also discusses use of peptides as anti-cancer vaccines and their efficiency as drug-delivery tools. We hope this work will give the reader a clear idea of the mechanisms of peptide-based anti-cancer therapeutics and encourage the development of superior drugs in the future. The Royal Society of Chemistry 2022-08-02 /pmc/articles/PMC9345020/ /pubmed/35975072 http://dx.doi.org/10.1039/d2ra02062a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Chemistry Bose, Debopriya Roy, Laboni Chatterjee, Subhrangsu Peptide therapeutics in the management of metastatic cancers |
title | Peptide therapeutics in the management of metastatic cancers |
title_full | Peptide therapeutics in the management of metastatic cancers |
title_fullStr | Peptide therapeutics in the management of metastatic cancers |
title_full_unstemmed | Peptide therapeutics in the management of metastatic cancers |
title_short | Peptide therapeutics in the management of metastatic cancers |
title_sort | peptide therapeutics in the management of metastatic cancers |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345020/ https://www.ncbi.nlm.nih.gov/pubmed/35975072 http://dx.doi.org/10.1039/d2ra02062a |
work_keys_str_mv | AT bosedebopriya peptidetherapeuticsinthemanagementofmetastaticcancers AT roylaboni peptidetherapeuticsinthemanagementofmetastaticcancers AT chatterjeesubhrangsu peptidetherapeuticsinthemanagementofmetastaticcancers |